Company Description
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.
The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.
The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19.
The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009.
Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
| Country | United States |
| IPO Date | Jun 15, 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. Christopher J. Schaber Ph.D. |
Contact Details
Address: 29 Emmons Drive, Suite B-10 Princeton, New Jersey 08540 United States | |
| Phone | 609-538-8200 |
| Website | soligenix.com |
Stock Details
| Ticker Symbol | SNGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000812796 |
| CUSIP Number | 834223307 |
| ISIN Number | US8342235053 |
| Employer ID | 41-1505029 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher J. Schaber Ph.D. | Chairman of the Board of Directors, Chief Executive Officer and President |
| Jonathan L. Guarino CPA, CGMA | Senior Vice President, Chief Financial Officer and Corporate Secretary |
| Dr. Oreola Donini Ph.D. | Senior Vice President and Chief Scientific Officer |
| Dr. Richard C. Straube M.D., MSc. | Senior Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 31, 2024 | 8-K | Current Report |
| May 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 28, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 24, 2024 | 8-K | Current Report |
| May 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 17, 2024 | 8-K | Current Report |
| May 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 15, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 10, 2024 | 424B3 | Prospectus |
| May 10, 2024 | 10-Q | Quarterly Report |